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(TRI) and transfemoral percutaneous coronary intervention (TFI) from a contemporary hospital
perspective.
Background Whereas the TRI approach to percutaneous coronary intervention (PCI) has been shown
to reduce access-site complications compared with TFI, whether it is associated with lower costs is
unknown.
Methods TRI and TFI patients were identiﬁed at 5 U.S. centers. The primary outcome was the cost of
percutaneous coronary intervention (PCI) hospitalization, deﬁned as cost on the day of PCI through
hospital discharge. Cost was obtained from each hospital’s cost accounting system. Independent costs
of TRI were identiﬁed using propensity-scoring methods with inverse probability weighting. Secondary
outcomes of interest were bleeding, in-hospital mortality, and length of stay, which were stratiﬁed by
pre-procedural risk and PCI indication.
Results In 7,121 PCI procedures performed from January 1, 2010, to March 31, 2011, TRI was
performed in 1,219 (17%) patients and was associated with shorter lengths of stay (2.5 vs. 3.0 days;
p < 0.001) and lower bleeding events (1.1% vs. 2.4%, adjusted odds ratio [OR]: 0.52, 95% conﬁdence
interval [CI]: 0.34 to 0.79; p ¼ 0.002). TRI was associated with a total cost savings of $830 (95% CI: $296
to $1,364; p < 0.001), of which $130 (95% CI: –$99 to $361; p ¼ 0.112) were procedural savings and
$705 (95% CI: $212 to $1,238; p < 0.001) were post-procedural savings. There was an associated
graded increase in savings among patients at higher predicted risk of bleeding: low risk: $642 (95%
CI: $43 to $1,236; p ¼ 0.035); moderate risk: $706 (95% CI: $104 to $1,308; p ¼ 0.029); and high
risk: $1,621 (95% CI: $271 to $2,971, p ¼ 0.039).
Conclusions TRI was associated with a cost savings exceeding $800 per patient relative to TFI.
Increased adoption of TRI may result in cost savings at hospitals. (J Am Coll Cardiol Intv
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828The frequency of transradial percutaneous coronary interven-
tion (TRI) is increasing in the United States (1). TRI is
associated with reduced access site bleeding complications
compared with transfemoral percutaneous coronary interven-
tion (TFI) (1–8). Moreover, TRI is associated with earlier
ambulation, reduced length of stay (LOS) and patient satis-
faction (4). Yet, proﬁciency in TRI requires overcoming
a deﬁned learning curve (9,10), which is associated with higher
percutaneous coronary intervention (PCI) failure rates initially
(5), resulting in increased access-site crossover (3,11), which is
associated with increased resource utilization (3,11,12).
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Although the clinical beneﬁt of TRI has been studied,
a contemporary and detailed cost analysis between TRI and
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Methods
The study population consisted of
a retrospective cohort of patients
undergoing PCI from January 1,
2010, to March 31, 2011, at 5
U.S. hospitals (Saint Luke’s Mid
America Heart Institute, Kansas
City,Missouri; SpectrumHealth,
Grand Rapids, Michigan; Wake
Forest Baptist Medical Center,
Winston-Salem, North Caro-
lina; Presbyterian Healthcare,Charlotte, North Carolina; Aurora Baycare Medical Center,
Green Bay, Wisconsin). Patients who underwent PCI at each
hospital were included. Patients who underwent >1 PCI
during admission were excluded because it is difﬁcult in such
cases to attribute an in-hospital bleeding event to a single
procedure. Patients with cardiogenic shock and chronic total
occlusion were also excluded. When >1 access site was used,nd Bremer are employees of ViTA Solutions,
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procedure is the access site used to perform the majority of the
procedure. The frequency of crossover was not collected.
In accordance with a data use agreement, a deidentiﬁed
limited dataset was obtained from each center with all
elements conforming to NCDR (National Cardiovascular
Data Registry) CathPCI Registry (version 4.0) data deﬁni-
tions (14). PCI procedure cost data were obtained directly
from each hospital’s cost accounting system and linked to the
limited dataset by a unique, randomly generated patient
identiﬁer. Neither the clinical nor the cost dataset contained
patient identiﬁable information. The analysis was then per-
formed on this combined dataset. Each respective hospital’s
institutional review board approved this study.
Hospital PCI costs. The primary outcome of interest was the
cost of PCI hospitalization, which was deﬁned as the cost on
the day of PCI through hospital discharge, from the
hospital’s perspective. Patient-level PCI costs were obtained
from the accounting system at each hospital and consisted of
equipment, resources, personnel, and other direct and
indirect costs. Because direct and indirect costs were ob-
tained from each hospital and were not uniformly deﬁned,
they were combined and included in total costs but not
individually analyzed. Because cost data are patient-level,
costs for bleeding and LOS were estimated through
regression cost modeling. Costs prior to the PCI procedure
were not included. Total costs were categorized as proce-
dural costs (incurred on the day of the procedure) and post-
procedural costs (incurred on the day after the procedure
through discharge). To normalize costs across hospitals to
the national average, the Dartmouth Atlas of Health Care
2009 county level price-, age-, sex-, and race-adjusted data
were applied (15). To remove extreme outliers, individual
hospital costs were trimmed to the 99th percentile.
Clinical outcomes. Secondary outcomes of interest were post-
PCI bleeding within 72 h, LOS, and in-hospital mortality
from all causes. Post-PCI bleeding was deﬁned in accordance
with CathPCI (version 4.0) as a suspected bleeding with
transfusion, a drop in hemoglobin of >3.0 g/dl, or a proce-
dural intervention to correct the bleeding event.
Statistical analysis. Demographic data are described as mean
 SD for continuous variables and number (percentage) for
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829chi-square tests, respectively. To obtain independent costs
for each access type and mitigate selection bias and con-
founding, a propensity score model was developed using
logistic regression to predict use of TRI from the following
variables: age; sex; race; insurance type; estimated glomerular
ﬁltration rate; ST-segment elevation myocardial infarction
(STEMI); non-STEMI; acute coronary syndromes; PCI
indication (elective, STEMI and non-STEMI); hyperten-
sion; prior PCI; peripheral vascular disease; prior heart
failure; glycoprotein IIb/IIIa inhibitor use; bivalirudin use;
low molecular weight heparin use; unfractionated heparin
use; Canadian Cardiovascular Society angina class; New
York Heart Association class; and number of stents used (as
a proxy for disease severity). A hierarchical generalized linear
mixed model was developed using inverse probability
weighting (IPW) (16) with total hospital cost as the
dependent variable and access location (TRI or TFI) as the
independent variable. Individual weights were stabilized to
account for the effect of extreme weights in the model (16).
Along with the IPW, additional covariates included: type of
anticoagulant; number of drug-eluting stents used; closure
device used; and PCI indication. To account for variation in
PCI costs across hospitals, a hierarchical modeling structure
with hospital site as a random effect was used. To ascertain
adequacy of the model with IPW, standardized differences
in covariate imbalances with and without the IPW are dis-
played in Online Figure 1 (17–19). Costs were trimmed
back to the 99th percentile to remove extreme outliers. Then
bootstrapping using 1,000 replicates with replacement was
applied to the model to account for skewness in the data
(20,21). Median, 2.5%, and 97.5% estimates were used to
determine the average costs and 95% conﬁdence intervals,
respectively. Patients were further stratiﬁed into low,
moderate, and high bleeding risk categories according to the
NCDR CathPCI bleeding risk model (22,23), with total,
procedural, and post-procedural costs analyzed for each
subgroup. To determine post-procedural TRI costs attrib-
utable to bleeding events and LOS, a “nested” modeling
approach was used, where bleeding and LOS variables were
added 1-by-1 as independent covariates to the existing cost
model and then compared to the original cost model. In the
ﬁrst model, in-hospital bleeding was added, and the change
in TRI post-procedural savings was deemed attributed to in-
hospital bleeding. The second model included in-hospital
bleeding and LOS, with the change attributed to LOS.
SECONDARY OUTCOMES. Other outcomes of interest in-
cluded: LOS; post PCI bleeding within 72 h; and in-
hospital mortality. Differences were estimated using IPW
hierarchical generalized linear multivariable regression
modeling (for LOS) and IPW hierarchical multivariable
logistic regression modeling (for bleeding and mortality).
Analyses were repeated for each bleeding risk. We also
tested an interaction term between TRI and bleeding risk inthe LOS model. Statistical signiﬁcance was deﬁned as p <
0.05. All analyses were performed at Saint Luke’s Mid
America Heart Institute using SAS (version 9.3, SAS
Institute, Cary, North Carolina).
Results
Demographic and descriptive statistics. The 5 sites per-
formed 7,121 (range: 418 to 2,862) eligible PCI procedures
from January 1, 2010, toMarch 31, 2011. TRI was performed
in 1,219 (17%) (range: 129 to 467; 11% to 38%) of all PCI
procedures. Clinical and demographic characteristics are
shown in Table 1. TRI patients were younger and less likely to
undergo primary PCI for STEMI; had fewer risk factors and
comorbidities such as hypertension, peripheral vascular
disease, and prior heart failure; and had higherGFR and lower
probabilities of bleeding. Unfractionated heparin (with or
without glycoprotein IIb/IIa) was more frequently used in
TRI, whereas bivalirudin was used less often (Table 1).
Bleeding and mortality outcomes. In-hospital bleeding
occurred in 1.1% of TRI and 2.4% of TFI procedures
(p ¼ 0.006). After IPW adjustment, the difference was
statistically signiﬁcant (odds ratio [OR]: 0.52, 95% conﬁ-
dence interval [CI]: 0.34 to 0.79; p ¼ 0.002). Unadjusted
in-hospital mortality occurred in 0.3% and 0.8%, respec-
tively (p ¼ 0.095).
Length of stay. LOSwas 2.5 days in the TRI group (95%CI:
2.09 to 2.89) comparedwith 3.0 days (95%CI: 2.60 to 3.35) in
the TFI group, a difference of 0.5 days favoring TRI (95%CI:
0.25 to 0.72; p< 0.001). The interaction term between access
location (radial or femoral) and bleeding risk was signiﬁcant
for the outcome of LOS (p ¼ 0.048). LOS was 0.31 days
shorter (95%CI: 0.12 to 0.50; p¼ 0.0015) in the low bleeding
risk group, 0.16 days shorter (95%CI: –0.20 to 0.52; p¼ 0.38)
in the moderate bleeding risk group, and 0.98 days shorter
(95% CI: 0.18 to 1.79; p ¼ 0.017) in the high bleeding risk
group. After adjustment, the differences narrowed but
remained statistically signiﬁcant (Table 2). The rate of same-
day discharge was 4.4% and 2.8% in the TRI and TFI groups,
respectively (p ¼ 0.001).
Hospital costs. Total unadjusted costs were $1,541 (95% CI:
$1,052 to $2,031; p < 0.001) lower in the TRI than the TFI
group. After risk adjustment, the difference decreased to
$830 (95% CI: $296 to $1,364; p < 0.001). Procedural cost
savings of $130 (95% CI: $99 to $361; p ¼ 0.112) with
TRI were not signiﬁcant, whereas post-procedural savings of
$705 (95% CI: $212 to $1,238; p < 0.001) were signiﬁcant.
In stepwise regression with nested models, 12% of the total
cost savings ($99) was attributable to decreased bleeding,
and 50% of the cost savings ($414) in TRI was due to the
0.38-day-shorter LOS.
Unadjusted and adjusted cost savings by bleeding risk
category are shown in Table 3. Greater savings were
observed as bleeding risk increased.
Table 1. Demographic and Clinical Characteristics
Total
(n ¼ 7,121)
Radial
(n ¼ 1,219)
Femoral
(n ¼ 5,902) p Value
Age, yrs 64.7  12.1 62.8  11.5 65.1  12.2 <0.001
Male 4,959 (69.6) 862 (70.8) 4,097 (69.4) 0.349
Race 0.306
Caucasian 6,487 (91.1) 1,122 (92.0) 5,365 (90.9)
African American 413 (5.8) 59 (4.8) 354 (6.0)
Asian 46 (0.6) 9 (0.7) 37 (0.6)
Native American 11 (0.2) 0 11 (0.2)
Other 164 (2.3) 29 (2.4) 135 (2.3)
Admission diagnosis <0.001
No angina 665 (9.3) 89 (7.3) 576 (9.8)
Symptoms unlikely 331 (4.7) 72 (5.9) 259 (4.4)
Stable angina 816 (11.5) 119 (9.8) 697 (11.8)
Unstable angina 3,007 (42.3) 513 (42.1) 2,494 (42.3)
Non-STEMI 1,329 (18.7) 331 (27.2) 998 (16.9)
STEMI 966 (13.6) 95 (7.8) 871 (14.8)
Indication for PCI <0.001
Elective 2,894 (40.7) 487 (40.0) 2,407 (40.8)
Urgent 2,503 (35.2) 507 (41.6) 1,996 (33.9)
Emergency 1,043 (14.7) 89 (7.3) 954 (16.2)
Salvage 674 (9.5) 136 (11.2) 538 (9.1)
Insurance type <0.001
Medicare/Medicaid 4,324 (60.7) 695 (57.0) 3,629 (61.5)
Private 2,307 (32.4) 432 (35.4) 1,875 (31.8)
Other 80 (1.1) 27 (2.2) 53 (0.9)
None 410 (5.8) 65 (5.3) 345 (5.8)
Hypertension 5,917 (83.1) 980 (80.4) 4,937 (83.7) 0.006
CCS class <0.001
No angina 1,775 (25.0) 321 (26.3) 1,454 (24.7)
Class 1 207 (2.9) 41 (3.4) 166 (2.8)
Class 2 603 (8.5) 60 (4.9) 543 (9.2)
Class 3 2,633 (37.0) 391 (32.1) 2,242 (38.0)
Class 4 1,896 (26.7) 406 (33.3) 1,490 (25.3)
NYHA class 0.047
None 6,384 (89.7) 1,110 (91.1) 5,274 (89.4)
Class I 114 (1.6) 25 (2.1) 89 (1.5)
Class II 115 (1.6) 11 (0.9) 104 (1.8)
Class III 212 (3.0) 32 (2.6) 180 (3.0)
Class IV 296 (4.2) 41 (3.4) 255 (4.3)
Previous PCI 2,971 (41.7) 498 (40.9) 2,473 (41.9) 0.499
Peripheral vascular disease history 1,128 (15.8) 145 (11.9) 983 (16.7) <0.001
Prior congestive heart failure 1,063 (14.9) 147 (12.1) 916 (15.5) 0.002
Estimated glomerular ﬁltration rate, ml/min/1.73 m2 76.2  26.9 81.5  26.5 75.1  26.9 <0.001
Missing 321 20 301
Imputed glomerular ﬁltration rate, ml/min/1.73 m2 76.1  26.3 81.4  26.3 75.0  26.2 <0.001
Admission status, in-patient 5,538 (77.8) 1,025 (84.1) 4,513 (76.5) <0.001
Same-day discharge 212 (3.0) 54 (4.4) 158 (2.7) 0.001
Continued on the next page
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830Discussion
This study provides a contemporary description of the costs
associated with TRI compared with TFI in patientsundergoing PCI. A novel ﬁnding is that TRI is associated
with cost savings of approximately $800 per PCI procedure.
The extent of cost savings increased substantially among
patients at higher bleeding risk. Finally, the cost savings
Table 1. Continued
Total
(n ¼ 7,121)
Radial
(n ¼ 1,219)
Femoral
(n ¼ 5,902) p Value
Anticoagulation and devices
Glycoprotein IIb/IIIa 1,744 (24.6) 406 (33.3) 1,338 (22.7) <0.001
Bivalirudin 3,520 (49.5) 515 (42.3) 3,005 (51.0) <0.001
Low molecular weight heparin 545 (7.7) 156 (12.8) 389 (6.6) <0.001
Unfractionated heparin 4,616 (64.9) 1,053 (86.4) 3,563 (60.5) <0.001
Closure device 3,425 (48.3) 16 (1.3) 3,409 (58.0) <0.001
Bare-metal stents used, n 0.3  0.7 0.3  0.7 0.3  0.7 0.147
Drug-eluting stents used, n 1.1  1.1 1.0  1.0 1.1  1.2 0.009
Total stents used, n 1.4  1.1 1.4  0.9 1.4  1.1 0.073
Bleeding risk
Probability, % 1.97  1.71 1.62  1.35 2.04  1.76 <0.001
Risk level <0.001
Low, <1% 2,292 (32.2) 469 (38.5) 1,823 (30.9)
Moderate, 1%–3% 3,541 (49.7) 607 (49.8) 2,934 (49.7)
High, >3% 1,288 (18.1) 143 (11.7) 1,145 (19.4)
Values are mean  SD or n (%).
CCS ¼ Canadian Cardiovascular Society; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial
infarction.
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831associated with TRI were mostly post-procedural, with
a minimal contribution from procedural costs, and were
principally driven by a major contribution from reduced
LOS.
Clinical implications. In the United States, more than
600,000 PCI are performed annually (24). Assuming TRI
use increases by 10%, from the current rate of 6.9% (25) (an
annual increase of approximately 60,000 TRI procedures),
U.S. hospitals could realize nearly $50 million in added
savings, assuming our data ($800). For hospitals performing
1,000 PCI procedures annually, a 10% to 20% TRI adoption
rate would imply incremental savings of $80,000 to
$160,000 per year. These potential savings are meaningful,Table 2. Length of Stay in All Patients and by Bleeding Risk a
n Radial
Unadjusted
All patients 7,121 2.49 (2.09 to 2.89)
Bleeding risk
Low, <1% 2,292 2.14 (1.89 to 2.38)
Moderate, 1% to 3% 3,541 2.72 (2.24 to 3.20)
High, >3% 1,288 3.04 (2.13 to 3.94)
Adjusted*
All patients 7,121 3.38 (2.92 to 3.83)
Bleeding risk
Low, <1% 2,292 2.71 (2.18 to 3.24)
Moderate, 1%–3% 3,541 3.42 (2.71 to 4.13)
High, >3% 1,288 3.74 (2.92 to 4.56)
Values are odds ratios (95% conﬁdence intervals). *Access site by bleeding inte
NCDR ¼ National Cardiovascular Data Registry.as hospitals modify stafﬁng and post-PCI discharge patterns
or initiate same-day discharge protocols.
Our study ﬁndings have even greater implications in the
current era of ongoing healthcare reform. Payment reforms
such as “per-episode” bundled payment and capitation, with
global payments or accountable care organizations are
currently under development and will likely replace the
traditional fee-for-service payment system (26–33). It is
thought that the strategies underlying accountable care
organizations and episode bundles, which are being piloted
as voluntary programs, will become a mandatory part of fee-
for-service physician payment in Medicare (with a parallel
program for hospitals termed “value-based purchasing”)s Estimated With the NCDR Model
Femoral Difference p Value
2.98 (2.60 to 3.35) 0.49 (0.25 to 0.72) <0.0001
2.45 (2.23 to 2.66) 0.31 (0.12 to 0.50) 0.0015
2.88 (2.47 to 3.29) 0.16 (–0.20 to 0.52) 0.3814
4.02 (3.39 to 4.65) 0.98 (0.18 to 1.79) 0.0171
3.76 (3.32 to 4.20) 0.38 (0.12 to 0.64) 0.005
3.11 (2.59 to 3.63) 0.40 (0.22 to 0.57) <0.001
3.51 (2.83 to 4.19) 0.09 (–0.37 to 0.55) 0.700
4.60 (3.84 to 5.35) 0.86 (0.25 to 1.46) 0.006
raction p ¼ 0.048 with main effects included in the model.
Table 3. Total Unadjusted and Adjusted Hospital Cost Savings in All Patients and by Bleeding Risk as Estimated
With the NCDR Model
n Radial Femoral
Difference: Radial
vs. Femoral p Value
Unadjusted costs
All patients 7,121 $14,441 ($12,281–$16,602) $15,983 ($13,847–$18,118) $1,541 ($1,052–$2,031) <0.001
Bleeding risk
Low, <1% 2,292 $13,919 ($11,866–$15,971) $14,690 ($12,673–$16,708) $771 ($156–$1,386) 0.014
Moderate, 1%–3% 3,541 $14,668 ($12,396–$16,940) $15,983 ($13,759–$18,207) $1,316 ($629–$2,003) <0.001
High, >3% 1,288 $15,361 ($12,673–$18,049) $17,749 ($15,423–$20,074) $2,388 ($654–$4,121) 0.007
Adjusted costs
All patients 7,121 $14,954 ($14,547–$15,383) $15,784 ($15,463–$16,105) $830 ($296–$1,364) <0.001
Bleeding risk
Low, <1% 2,292 $14,074 ($13,590–$14,575) $14,716 ($14,234–$15,210) $642 ($43–$1,242) 0.035
Moderate, 1%–3% 3,541 $15,161 ($14559–$15,824) $15,867 ($15,388–$16,331) $706 ($104–$1,308) 0.029
High, >3% 1,288 $16,115 ($14,899–$17,612) $17,776 ($16,815–$18,814) $1,621 ($271–$2,971) 0.038
Values are median (interquartile range).
NCDR ¼ National Cardiovascular Data Registry.
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832(34). Our study shows substantial cost savings to hospitals
with TRI and offers a solution for reducing costs of PCI,
especially when combined with same-day discharge. The
magnitude of cost savings is large and should be of
considerable interest to policy makers, payers, and, most
importantly, hospitals implementing TRI programs.
There were fewer bleeding complications associated with
TRI in the present study, which is consistent with results
from the RIVAL (Radial Versus Femoral Access for
Coronary Angiography and Intervention in Patients With
Acute Coronary Syndromes) study (5). Both the direction
and magnitude of reduced bleeding in this study are also
consistent with previous randomized and observational
studies comparing TRI with TFI (5,6,8,13). Particularly
noteworthy, the observed bleeding reduction in the TRI
group was achieved despite frequent use of other bleeding
avoidance strategies (e.g., 51% bivalirudin use, 58% closure
devices) in the TFI group.
This study suggests that the major contributor to the cost
savings of TRI is related to reducing LOS. This ﬁnding
persisted despite only 4% of TRI patients being discharged
the same day in our study. Lower bleeding rates only
contributed marginally, and there was only a small contri-
bution from reduced procedural costs. As hospitals
increasingly use same-day discharge protocols (35–37) for
TRI patients, LOS will expectedly decrease, and greater cost
savings attributable to TRI will likely increase further (38).
Study limitations. First, the observational nature of these
data may be subject to selection bias and unmeasured
confounding, despite rigorous propensity score methods
with IPW to adjust for confounding associated with
TRI use. Given the nonrandomized nature of this study,
an unmeasured confounder may have affected physicianchoice, both for the use of transradial or transfemoral access
and the timing of discharge. Given that the TRI cohort was
somewhat lower risk, physicians may be more apt to
discharge patients earlier to home, which may partially
account for the cost differences noted in this study.
However, it should also be noted that when transfemoral
patients are dismissed to home on the same day, it is likely
that patients received a vascular closure device that would
drive up procedurally related costs for the TFI cohort. Data
from these hospitals may not be generalizable to other U.S.
practices in the early stages of TRI adoption, given the
expected learning curve associated with TRI (9,10,39),
which is associated with higher rates of crossover and
procedural failure. The cost savings may depend on either
shortening the learning curve or not being fully realized
until adequate learning has been achieved. To account for
these limitations, we intentionally included data from 5
hospitals with varying PCI volumes and TRI expertise,
a hierarchical modeling structure that adjusts for the effect
of site, and bias-corrected bootstrap resampling to yield
more generalizable costs for TRI and TFI. Third, the costs
demonstrated here are from the hospital perspective. A
broader societal-level perspective may be preferable, as
downstream costs or savings associated with TRI are
possible. We also chose not to provide an analysis from the
payer’s perspective, as hospital reimbursement for TRI and
TFI are the same. Additionally, we did not capture cross-
over. Therefore, some variation may exist in reported rates
of TRI and TFI where an operator switched access sites
during a given procedure. Finally, we were unable to
prospectively study quality of life data, which limits a more
comprehensive cost-utility evaluation. However, because
transradial access in general has been shown to result in
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833increased patient satisfaction, we believe any quality of life
data would further favor TRI (4).Conclusions
TRI is associated with signiﬁcantly lower costs than is
TFI when examined from a hospital perspective. Most of
these cost savings were driven by reduced LOS during the
post-procedural period, with lesser savings from reductions
in bleeding. The magnitude of cost savings, which exceeded
$800 per PCI, may be appealing to hospitals that consider
adopting TRI for PCI.Acknowledgments
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